KMPH News and Press, KemPharm Inc From 07/15/21

KemPharm (NASDAQ: KMPH) , a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, has announced its entry into agreements with certain of its holders of its existing warrants exercisable for 6,117,509 shares of its common stock, in the aggregate....

KemPharm develops prodrugs of approved drugs. It has multiple approvals under its belt. Cash position is also decent. For further details see: KemPharm - Redesigning Approved Drugs For Better Efficacy And Safety

Shares of KemPharm (NASDAQ: KMPH) were sinking 12.6% as of 3:33 p.m. EDT on Friday. The big drop came after the drugmaker announced the exercise of existing warrants and the issuance of new warrants. A warrant gives the right to buy a stock at a set price and set date. In KemPha...

Gainers: Geron (GERN) +48%.CAI International (CAI) +46%.Sykes Enterprises (SYKE) +30%.PDS Biotechnology (PDSB) +18%.Smith & Wesson Brands (SWBI) +17%.Biophytis (BPTS) +13%.SemiLEDs (LEDS) +10%.Clean Energy Fuels (CLNE) +10%.Luokung Technology (LKCO) +10%.Vinco Ventures (BBIG) +9%.Los...

Gainers: Geron (GERN) +22%, AnPac Bio-Medical Science (ANPC) +20%, CureVac (CVAC) +13%, Crinetics Pharmaceuticals (CRNX) +7%, Seres Therapeutics (MCRB) +7%.Losers: Orphazyme (ORPH) -41%, Athira Pharma (ATHA) -41%, Chinook Therap...

KemPharm ([[KMPH]] -2.4%) has entered into agreements with certain of its holders of existing warrants exercisable for 6.12M shares.The holders have agreed to exercise their warrants for cash in exchange for the company’s agreement to issue in a private placement new warrants to p...

CELEBRATION, Fla., June 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced it has entered into agreements with certain of its holders of its existing warrants exerci...

In accordance with the 2021 Russell indexes annual reconstitution, KemPharm (KMPH) expects its addition to the broad-market Russell 3000 Index and the Russell 2000 indexThe company will be added to Russell indexes effective after the U.S. market opens on Monday, June 28, 2...

CELEBRATION, Fla., June 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today its expected addition to the broad-market Russell 3000 ® Index and the Russe...

CELEBRATION, Fla., June 03, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm,...